Combined Perifosine (Pi3k/Akt Inhibitor) And Radiotherapy For Prostate Cancer

Y. Gao,X. Wang,J. Zhu,W. Mai,Y. Huang,D. Floryk,M. Ittmann,T. Thompson,E.B. Butler,B.S. Teh

DOI: https://doi.org/10.1016/j.ijrobp.2008.06.546

2008-01-01

Abstract:Prostate cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality among American men. Radiotherapy is a very important treatment modality for prostate cancer. A new generation of biological response modifiers, such as membrane-targeted alkylphospholipid perifosine, has emerged and may increase the anti-tumor effects of radiotherapy. This study is to investigate whether perifosine, with the inhibition of the PI3K/AKT signaling pathway, can enhance the effect of radiation against human prostate cancer. Human prostate cancer cell line CWR22RV1 was treated with PI3K/AKT inhibitor perifosine, radiation, and combination of the two therapies respectively. Clonogenic survival assay, sulforhodamine B cytotoxity assay and cell density assay were used for in-vitro assessment. Apoptosis measurement, cell cycle analysis with flow cytometry and Western blot were used for evaluating the mechanisms of actions. Tumor growth delay assay was used for in vivo experiments. The combination of perifosine and radiation caused further significant decrease in clonogenic survival when compared with radiation alone in CWR22RV1 cell line. Cell viability determined by MTS assay and cell density assessed by counting adherent cells both showed significant inhibition (in a synergistic manner) of cell proliferation in the combined radiation and perifosine group when compared with radiation or perifosine alone groups. Marked increase in apoptosis was noted in the combined group when compared with radiation or perifosine alone groups. Decrease in the expression of phospho-AKT-T308 and phospho-AKT-S473 were detected in cells 24 hours after treated with 5μM perifosine. Radiation had no effect on the expression of AKT or phospho-AKT. The expression of phospho-AKT-T308 and phospho-AKT-S473 were significantly decreased in the combined group when compared to perifosine alone group. The expression of cleaved caspase 3 was noted to be highest in the combined group when compared with radiation or perifosine alone groups. In vivo, the growth of implanted tumors showed the most significant inhibition in the combined radiotherapy and perifosine group when compared with control, radiation or perifosine alone groups. Both in vitro and in vivo experiments demonstrate that combining irradiation with perifosine enhance the radiation anti-tumor efficacy in the human prostate cancer model through inactivation of AKT leading to significant apoptosis. Clinical trial integrating perifosine with radiotherapy for prostate cancer is planned.